摘要
目的评价阿立哌唑治疗精神分裂症的疗效及安全性。方法将符合CCMD-3精神分裂症诊断标准的80例门诊及住院病人随机分成2组,其中研究组(40例)和对照组(40例),分别服用阿立哌唑和利培酮。研究时间为8周,以PANSS量表评估2组的疗效,以TESS(治疗中出现的不良反应量表)评定安全性。结果研究组和对照组疗效分别为78.9%和73.7%,差异无统计学意义,2组总体不良反应发生率差异无统计学意义。结论阿立哌唑治疗精神分裂症疗效好,安全性高,依从性好。
[ Objective ] To evaluate the efficacy and safety of aripiprazole in treatment of schizophrenia. [ Methods ] 80 outpatients and inpatients with schizophrenia which diagnosis by CCMD 3 were randomly divided into the study group {40 cases） and the control group （40 cases） , which treated by aripiprazole and risperidone respectively. The research time was 8 weeks. The efficacy and safety were evaluated by PANSS scale and TESS scale respectively. [ Results ] The efficacy rate of the study group and the control group was 78.9% and 73.7% respectively. There was no significant difference in efficacy rate between two groups. The difference in total incidence of adverse reaction between two groups was no significant. [ Conclusion ] Aripiprazole is a medicine with good efficacy, high safety and good compliance in treatment of schizophrenia.
出处
《职业与健康》
CAS
2009年第10期1108-1109,共2页
Occupation and Health
